Xarelto: Latest News

Xarelto blood thinning medication continues to be the subject of lawsuits due to its dangerous bleeding risks, with no approved antidote to date. Janssen Pharmaceuticals (Johnson & Johnson subsidiary) and Bayer Corporation are now the subjects of consolidated lawsuits on behalf of patients injured by the commonly prescribed drug. Xarelto has been common to complaints of internal bleeding, including gastrointestinal bleeding and brain bleeding, as well as death. Federal judges have found that a large enough number of the lawsuits includes common complains and similar facts, including the possibility that the drugs were not labeled with the dire warning of severe bleeding possibilities as a large side effect.

Xarelto has been approved by the Federal Drug Administration (FDA) for use to reduce stroke risk in those patients who have non-valvular atrial fibrillation; for treatment of deep vein thrombosis; for treatment of pulmonary embolism; for reducing the return of the aforementioned conditions; and for prevention of blood clots following knee or hip replacement surgeries. In fact, Xarelto can increase the risk of blood clots when its therapeutic use is stopped prematurely and it also carries the risk of causing epidural or spinal hematomas that could lead to permanent paralysis when used by those also receiving neuraxial anesthesia or those who undergo spinal puncture. These dangerous risks have led to the FDA issuing Black Box warnings, which are the most serious warnings that the FDA issues, reserved for products that pose a really significant risk of serious to life-threatening effects.

Inserra & Kelley is already a part of the fight waged on behalf of patients injured by Xarelto. If you or a loved one has been affected by a serious or fatal bleeding event with the use of Xarelto, do not hesitate to contact us for timely, caring, expert advice on your individual case.